<i>Journal of Hepatology</i>｜Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy

doi:10.12449/JCH2411.gwqkjpwzjj2

Volume 40 Issue 11

Nov. 2024

Turn off MathJax

Article Contents

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(11): 2237-2237

PDF( 1225 KB)

Journal of Hepatology｜Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy

DOI: 10.12449/JCH2411.gwqkjpwzjj2

Published Date: 2024-11-25

Abstract

FullText(HTML)

References(0)

References

Relative Articles

[1]	Xieer LIANG, Zhihong LIU, Jinlin HOU. New drugs for the functional cure of hepatitis B: Focusing on antisense oligonucleotides and small interfering RNAs[J]. Journal of Clinical Hepatology, 2025, 41(1): 7-14. doi: 10.12449/JCH250102
[2]	Journal of Hepatology｜Association of food insecurity with the prevalence and liver-related mortality of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. Journal of Clinical Hepatology, 2024, 40(10): 2126-2126. doi: 10.12449/JCH2410.gwqkjpwzjj3
[3]	Hepatology International｜Functional B cell deficiency promotes intrahepatic HBV replication and impairs the development of anti-HBV T cell responses[J]. Journal of Clinical Hepatology, 2024, 40(12): 2360-2360. doi: 10.12449/JCH2412.gwqkjpwzjj1
[4]	Journal of the American Medical Association｜Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: A randomized clinical trial[J]. Journal of Clinical Hepatology, 2024, 40(8): 1652-1652. doi: 10.12449/JCH2408.gwqkjpwzjj3
[5]	Journal of Hepatology｜Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer[J]. Journal of Clinical Hepatology, 2024, 40(9): 1872-1872. doi: 10.12449/JCH2409.gwqkjpwzjj3
[6]	Hong NIE, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of tyrosine kinase inhibitor combined with immune checkpoint inhibitor as the second-line therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(8): 1620-1626. doi: 10.12449/JCH240818
[7]	Journal of Hepatology｜Baveno Ⅶ algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(5): 1003-1003. doi: 10.3969/j.issn.1001-5256.2023.05.gwjpwzjj1
[8]	Journal of Hepatology ｜ Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(1): 151-151. doi: 10.3969/j.issn.1001-5256.2023.01.gwjpwzjj3
[9]	Hepatology International｜Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial[J]. Journal of Clinical Hepatology, 2023, 39(10): 2431-2431. doi: 10.3969/j.issn.1001-5256.2023.10.gwjpwzjj1
[10]	Yucheng HOU, Hongqiang ZHAO, Caoer DONG, Guangdong WU, Xuan TONG, Ang LI, Qian LU, Hong CHEN, Rui TANG. Research advances in immune checkpoint inhibitor-related cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(2): 463-468. doi: 10.3969/j.issn.1001-5256.2023.02.034
[11]	Shun CHEN, Youcheng XIE, Junke WANG, Baoyin ZHAO, Jiucong ZHANG, Pan WANG, Xiaohui YU. Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation[J]. Journal of Clinical Hepatology, 2023, 39(6): 1424-1430. doi: 10.3969/j.issn.1001-5256.2023.06.027
[12]	Youcheng XIE, Shun CHEN, Chuyi LI, Ying ZHENG, Dong JIA, Jiucong ZHANG, Xiaohui YU. Application of immune checkpoint inhibitors in liver transplantation for patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 941-947. doi: 10.3969/j.issn.1001-5256.2023.04.030
[13]	Journal of Hepatology｜Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection[J]. Journal of Clinical Hepatology, 2022, 38(12): 2727-2727. doi: 10.3969/j.issn.1001-5256.2022.12.gwjpwzjj1
[14]	Journal of Gastroenterology and Hepatology｜Rifampicin can improve cholestasis in patients with persistent hepatocellular secretory failure[J]. Journal of Clinical Hepatology, 2022, 38(2): 396-396. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj4
[15]	Guoming SHI, Yanzhi PEI, Pinxiang LU, Jun CAO, Jian ZHOU, Jia FAN. Immune checkpoint inhibitors for treatment of biliary malignant tumors[J]. Journal of Clinical Hepatology, 2022, 38(5): 998-1001. doi: 10.3969/j.issn.1001-5256.2022.05.005
[16]	Yu WANG, Zhaoying LI, Shuang LI, Chenghai LIU. Research advances in adverse liver reactions caused by immune checkpoint inhibitors[J]. Journal of Clinical Hepatology, 2022, 38(1): 220-223. doi: 10.3969/j.issn.1001-5256.2022.01.039
[17]	Dan LIU, Tiantian YAO, Yuhan ZHANG, Guiqiang WANG, Yan WANG. Efficiency and safety of immune checkpoint inhibitors in cancer patients with chronic liver disease: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(11): 2457-2461. doi: 10.3969/j.issn.1001-5256.2022.11.005
[18]	Journal of Gastroenterology and Hepatology｜Compared with chemotherapy alone as the first-line treatment, PD-1 inhibitor combined with chemotherapy can significantly improve the median progression-free survival time of patients with metastatic or recurrent cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(2): 401-401. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj5
[19]	Hanping WANG. Adverse reactions associated with immune checkpoint inhibitor in treatment of liver cancer and related treatment measures[J]. Journal of Clinical Hepatology, 2022, 38(5): 985-991. doi: 10.3969/j.issn.1001-5256.2022.05.003
[20]	Sun Tao, Ren YanQiao, Cao YanYan, Zheng ChuanSheng. Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1386-1388. doi: 10.3969/j.issn.1001-5256.2020.06.043

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (129) PDF downloads(22)

Journal of Hepatology｜Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy

DOI: 10.12449/JCH2411.gwqkjpwzjj2

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Journal of Hepatology｜Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy

DOI: 10.12449/JCH2411.gwqkjpwzjj2

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content